Oyster Point Pharma, Inc. — Form D
Oyster Point Pharma, Inc. of PRINCETON, NJ, a company, filed a Form D exempt-offering notice with the SEC on 2019-02-27. The offering totals $93.0M, of which $85.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2019-02-27
- Form: D
- Accession: 0001720725-19-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $93.0M
- Amount sold: $85.0M
- Remaining: $8.0M
- Investors: 7
- Date of first sale: 2019-02-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-333703
Issuer
- Name: Oyster Point Pharma, Inc.
- CIK: 0001720725
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 700 ALEXANDER PARK DRIVE, PRINCETON, NJ, 08540
- Phone: (609) 382-9032
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| D. Michael Ackermann | Director | Princeton, NJ |
| Ali J Behbahani | Director | Princeton, NJ |
| William J Link | Director | Princeton, NJ |
| Mark A Murray | Director | Princeton, NJ |
| Jeffrey A Nau | Director | Princeton, NJ |
| Clare A Ozawa | Director | Princeton, NJ |
| Benjamin A Tsai | Director | Los Angeles, CA |
| Mark A Murray | Executive Officer | Princeton, NJ |
| Jeffrey A Nau | Executive Officer | Princeton, NJ |
Other filings by this issuer (1)
More